^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Published date:
06/04/2020
Excerpt:
Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS....In patients with wild-type or mutant BRAF tumors, median OS was 13.8 months (95% CI 10.2 to 17.0) and 33.2 months (95% CI 19.4 to 45.2) in the 10 mg/kg group, and 11.2 months (95% CI 9.2 to 13.8) and 19.7 months (95% CI 11.6 to 25.3) in the 3 mg/kg group, respectively.
DOI:
10.1136/jitc-2019-000391
Trial ID:
Source:
Title:
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Excerpt:
...- Either treatment naïve or received only one line of systemic anticancer therapy if v-raf murine sarcoma viral oncogene homolog B1 (BRAF) wild-type or up to two lines of systemic anticancer therapy including one BRAF inhibitor-containing regimen if BRAF mutant....
Trial ID:
Source:
Title:
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Excerpt:
...- Tumor may have a B-RAF V600 mutation or be BRAF wild type, and patients must...
Trial ID:
More C2 evidence
Source:
Title:
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Excerpt:
...- Histologic diagnosis of malignant melanoma tested positive for the BRAF V600 mutation...
Trial ID:
